in vivo studies, endotoxin affinity beads were used to remove endotoxin from all protein variants.
The final endotoxin concentration was measured by Toxin Sensor TM Chromogenic LAL Endotoxin
Assay Kit (Genscript, Nanjing, China). The results showed that the endotoxin level was less than 0.1 EU/mL, significantly below the safety limit required for medical devices and parenteral drugs (0.5 EU/mL according to FDA of U.S.A.).
Instrumentation. Tandem gel permeation chromatography (GPC) experiments were performed on a system equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA), a DAWN HELEOS 9-angle laser light scattering detector (Wyatt Technology, Santa Barbara, CA) and an Optilab rEX refractive index detector (Wyatt Technology, Santa Barbara, CA). The detection wavelength of HELEOS was set to 658 nm. Separations were performed on serially connected size exclusion columns (10 3 Å, 10 4 Å, 10 5 Å Phenogel columns, 5 µm, 7.8 × 300 mm, Phenomenex, Torrance, CA) at 50 °C using 0.1 M LiBr in DMF as the mobile phase. FPLC separation was performed on an ÄKTA FPLC system (GE Healthcare, Inc.) using a Superdex 200 Increase 10/300 GL column or MonoS 5/50 GL column. Protein concentration was quantified by NanoPhotometer TM P-class (Germany). SDS-PAGE gel was recorded on a typhoon FLA 9500 laser scanner (GE Healthcare Corp. 
Synthesis of L-and DL-P(EG3Glu).
In a glovebox, L-EG3-GluNCA (82.2 mg, 0.258 mmol, 100 equiv) in anhydrous DMF (800 μL) was mixed with phenyl trimethylsilyl sulfide (PhS-TMS, 5.1 μL, 0.5 M, 1.0 equiv). After stirring at room temperature for 48 h, the desired product denoted as L-P(EG3Glu) was recovered by precipitation in diethyl ether (40 mL), washed with diethyl ether (40 mL × 2), and passed through a PD-10 SEC column. The final product was obtained as a colorless gum-like solid after lyophilization (52 mg, yield 71%). DL-P(EG3Glu) were synthesized by following a similar protocol except that racemic DL-EG3-GluNCA were used as the monomer. PEG20k-IFN was synthesized following a similar protocol with mPEGCOS n Bu (5.0 equiv) and purified with a monoS 5/50 GL column, yield ~49%.
The GH series L20k-GH, DL20k-GH and PEG20k-GH were also synthesized by following the same protocol, purification yield ~50-70%. Tumor volume was calculated by the following formula:
Statistical analyses were performed using GraphPad Prism software 5.0 and data were expressed as mean ± S.D. The immunization of L20k-GH, DL20k-GH, or PEG20k-GH was performed by following a similar protocol with a dose of 0.4 mg/kg. Apart from the regular blood collection every week, sera were also collected at selected time points after the 1 st and 3 rd infusion for the study of accelerated blood clearance effect. The plasma GH level was analyzed by Human Growth Hormone ELISA kit S10 (Boster). The ELISA analyses of anti-GH and anti-polymer antibodies in sera extracted from rats were performed in a similar protocol as described above.
Recipes of buffers used in ELISA: Figure S11 . Anti-polymer ELISA assays using free DL-P(EG3Glu) (A) or PEG (B) as the competition agent; the plates were coated with DL20k-IFN or PEG20k-IFN; sera immunized with DL20k-GH or PEG20k-GH (week 4) were pre-diluted 200-fold and incubated with the corresponding free polymer at gradient concentrations. Table S1 AUC0-24h of GH-polymer conjugates at the1 st and the 3 rd dose
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Data are expressed as mean ± S.D.
